AP
Apogee Therapeutics, Inc.
APGE · NASDAQ
$135.07 +0.01% (+$0.01)
1M +0.21%
Market Cap $8.36B
P/E Ratio -
Div. Yield -
ROE 29.88%
Piotroski F-Score Weak
2/9Valuation
13 /100
Expensive P/B 7.00x
EV/EBITDA N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 85.30%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 29.88%
ROA 22.04%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 26.44x
Int. coverage -185.14x
Debt/Equity 0.01x
Stability
33 /100
Unstable EPS volatility 44.58%
Profitable years 0
Beta 0.34x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o APGE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Thomas Henderson
Employees
261
Headquarters
Waltham
Nadchodzące wydarzenia
09 LIS
Earnings
Upcoming earnings report